SCHEMBL3245578

SCHEMBL3245578

CC1(C)NC(=O)N(CCS(=O)(=O)O)C1=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
KMT2A Q03164 3/20 0.51
PADI4 Q9UM07 1/20 0.45
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 5/20 0.43
PLA2G7 Q13093 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALOX15 P16050 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2208602 0.77 ALDH1A1 (0.40) POLBKMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL11694927 0.77 POLB (0.68) POLBKMT2APADI4LMNAALDH1A1
Methane SCHEMBL11598388 0.76 POLB (0.61) POLBKMT2APADI4MEN1LMNA
SCHEMBL9787811 0.75 POLB (0.65) POLBKMT2APADI4LMNAALDH1A1
SCHEMBL11694716 0.75 POLB (0.65) POLBKMT2APADI4LMNAALDH1A1
SCHEMBL2434763 0.73 POLB (0.63) POLBKMT2APADI4MEN1LMNA
SCHEMBL16674724 0.73 POLB (0.63) POLBKMT2APADI4MEN1LMNA
SCHEMBL18768302 0.73 POLB (0.57) POLBKMT2APADI4MEN1LMNA
SCHEMBL8165986 0.73 KMT2A (0.68) POLBKMT2APADI4MEN1LMNA
SCHEMBL2185850 0.72 PLA2G7 (0.32) PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
WO-2010054009-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS OXA1L, NISCH, ODC1 POLB 1432/4885KMT2A 2188/4885PADI4 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.